News

December 12, 2019

Conference Call to Discuss ALX148 Clinical Program  Webcast audio   View slides

December 7, 2019

ALX Oncology Presents Initial Data from the ALX148 Clinical Trial Non-Hodgkin Lymphoma Combination Cohort at the 61st American Society of Hematology (ASH)  Read more   Download

November 14, 2019

ALX Oncology to Present ALX148 Clinical Data at the 61st American Society of Hematology Annual Meeting (ASH)  Read more   Download

November 6, 2019

ALX Oncology Presents Clinical Biomarker Data From ALX148 Clinical Trial Solid Tumor Combination Cohorts at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)  Read more   Download

October 2, 2019

ALX Oncology to Present ALX148 Clinical Biomarker Data at the 34th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)  Read more   Download

August 12, 2019

Eat This, Don’t Eat That: CD47 Companies’ First Hurdle  Read article (BioCentury 2019)

June 1, 2019

ALX Oncology Presents New Data from Fully Enrolled ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors   Read more   Download

May 31, 2019

ALX Oncology to Present at Jefferies 2019 Healthcare Conference   Read more   Download

May 16, 2019

ALX Oncology to Present ALX148 Clinical Data at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting   Read more   Download

February 27, 2019

ALX Oncology to Present Preclinical Data on SIRPα Antibody Program at Upcoming Conferences   Read more   Download

November 7, 2018

ALX Oncology Presents Updated Data from ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors   Read more   Download

August 22, 2018

ALX148 Blocks CD47 and Enhances Innate and Adaptive Antitumor Immunity with a Favorable Safety Profile  Read article (PLOS ONE)

June 24, 2018

VIDEO LINK: ALX148 Clinical Program Overview By Sophia Randolph, MD, PhD, Chief Medical Officer at ALX Oncology  View video (Healio)

June 22, 2018

Alexo Therapeutics Changes Name to ALX Oncology   Read more   Download

June 4, 2018

Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma   Read more   Download

May 17, 2018

Alexo Therapeutics Initiates ALX148 Clinical Trial Combination Cohorts for the Treatment of Patients with Advanced Solid Tumors and Lymphoma   Read more   Download

December 9, 2017

Alexo Therapeutics Presents Preclinical Data Demonstrating that ALX148 Bridges Innate and Adaptive Immunity to Enhance Antitumor Immune Response at the 59th Annual ASH Meeting   Read more   Download

November 13, 2017

Alexo Therapeutics to Present ALX148 Preclinical Data at the 59th American Society of Hematology Annual Meeting (ASH)  Read more   Download

November 10, 2017

Alexo Therapeutics Presents Preliminary Results from ALX148 Phase 1 Clinical Trial in Patients with Advanced Solid Tumors and Lymphoma  Read more   Download

October 5, 2017

Alexo Therapeutics to Present ALX148 Clinical Data at the 32nd Annual Meeting of the Society for Immunotherapy of Cancer (SITC)  Read more   Download

April 10, 2017

Alexo Therapeutics Announces Initiation of Phase 1 Clinical Trial of ALX148 for the Treatment of Advanced Solid Tumors and Lymphoma  Read more   Download

July 25, 2016

BioCentury Emerging Company Profile of Alexo Therapeutics  Read article

Upcoming Events

No events scheduled at this time.